PE-22-28
Spadin-derived TREK-1 blocker — research-stage antidepressant peptide. Animal data only.
- Half-life
- Not established
- Out of system
- —
- Route
- Subcutaneous
- Level
- Advanced
What PE-22-28 is used for
- Research-stage rapid-acting antidepressant mechanism (TREK-1 blockade)
- Promising antidepressant + anxiolytic signals in rodent studies
How it's typically used
No established human protocol. Reported research range: ~0.5 mg subcutaneous daily.
What to watch for
- Animal data only — no human safety, dosing, or efficacy established
- Do not combine with prescribed antidepressants without a clinician
- Not approved for human use; experimental
About Other research compounds
- What they are
- Nootropics, metabolic agents, and research compounds that don't fit the other classes.
- How they're run
- Route and schedule vary widely — check the individual entry.
- What to watch
- This is the least-characterised corner of the atlas. Read the full guide, and treat anything without published human data as exactly that.
Full guide
PE-22-28: A Tracking Guide for a Research-Stage Antidepressant Peptide
A spadin analog that targets TREK-1. What the mechanism implies, why it is research-only, and what to log.
Other other research compounds
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.